The Short or Long Term Debate24 Mar 2021 15:01
There is a saying that, "A long term investment is a short term investment that didn't work out." However, it's good to try and work out what the short, medium and long term things are. No point dwelling too long on the unknowns as curve balls get thrown at investors regularly, then it's important to assess the impact quickly and adapt your strategy if needed.
I suspect people looking to be long term from here are looking for HEMO to succeed in at least one area they are currently in. There are quite a few pies with fingers in and any might be commercially successful but trials, without immense government backing, as win the Covid vaccines, take years. Pre-clinical, then Phase 1, Phase 2, Phase 3, submission to FDA/MHRA/EMA/other, etc. things can fail at any point but success at each point gives a boost to the shareprice. Staying to the end is a trial of faith that holdings will not be diluted until the first commercial success to the point that they are not worth as much as when bought, even with the mcap is 10x the point of investment. The company may succeed in more than one area and that is a great thing for mankind but is it a good thing for shareholders here now or looking to buy now for that possible future?
My feeling for medium term people may not be looking for commmercialisation of one or more development streams but the success of one of those milestones and maybe then unload and reload at some point for the next one. They may not stay in medium term but have a medium term view to a potential series or short term positions.
Short termers watch and stay out and try to time the milestone events to avoid being in when dilution strikes and aim to tie up funds for no more than a week or two.
What are the knowns here for development? A deal is supposed to be done in the next couple of weeks with E-L that is an event. Some things should be going into trials but outcomes are not known.
What knowns for dilution? There is £11.35m outstanding of a convertible loan for which the maximum conversion price is 8.4375p that equates to very nearly 135m shares for a company with 455m that's some dilution and any good news on sp could be held back by this factor. It's near certain that other tranches will need to be taken as HEMO are not profitable and until they can self-fund then the CLN and the market will be the source of income size of tranche and the value of conversion is unknown at this point.
What does this mean for the SP in the medium term? There could be another £48m of convertible loan notes executed before the CLN agreement is exhausted. The SP can rise significantly and stay risen only between tranches of the CLN being fully paid off and before the next tranches is taken. The point at which a tranche is taken determines the maximum price of conversion for that tranche and the SP will act as an anchor to a piece of hard to break elastic for any rise above that until paid off.